Literature DB >> 8840307

A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism.

I Martinez1, R Saracho, J Montenegro, F Llach.   

Abstract

Secondary hyperparathyroidism (HPT) develops early in chronic renal failure (CRF) at a time when plasma calcitriol levels are normal. At this time, PTH are higher than normal controls and serum phosphorous levels are lower. A decrement in total serum Ca is noted, after an oral phosphate load, only in patients with ERF. These data suggest that factors, other than a decrease in calcitriol synthesis, may be involved in the pathogenesis of HPT. A hypothesis is forwarded suggesting that an alteration in the newly cloned calcium sensor receptor may be the earliest abnormality in the HPT, preceding a decrease in plasma calcitriol levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840307     DOI: 10.1093/ndt/11.supp3.22

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  13 in total

1.  Excess 25-hydroxyvitamin D3 exacerbates tubulointerstitial injury in mice by modulating macrophage phenotype.

Authors:  Yasuo Kusunoki; Isao Matsui; Takayuki Hamano; Akihiro Shimomura; Daisuke Mori; Sayoko Yonemoto; Yoshitsugu Takabatake; Yoshiharu Tsubakihara; René St-Arnaud; Yoshitaka Isaka; Hiromi Rakugi
Journal:  Kidney Int       Date:  2015-07-15       Impact factor: 10.612

Review 2.  Vitamin D and its analogs in chronic renal failure.

Authors:  E Slatopolsky; A J Brown
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 3.  Cytochrome P450-mediated metabolism of vitamin D.

Authors:  Glenville Jones; David E Prosser; Martin Kaufmann
Journal:  J Lipid Res       Date:  2013-04-06       Impact factor: 5.922

4.  Relationship of 1,25 dihydroxy Vitamin D Levels to Clinical Outcomes in Critically Ill Patients with Acute Kidney Injury.

Authors:  Anitha Vijayan; Tingting Li; Adriana Dusso; Sanjay Jain; Daniel W Coyne
Journal:  J Nephrol Ther       Date:  2015-02

5.  The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification.

Authors:  G London; D Coyne; K Hruska; H H Malluche; K J Martin
Journal:  Clin Nephrol       Date:  2010-12       Impact factor: 0.975

6.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Authors:  Tamara Isakova; Patricia Wahl; Gabriela S Vargas; Orlando M Gutiérrez; Julia Scialla; Huiliang Xie; Dina Appleby; Lisa Nessel; Keith Bellovich; Jing Chen; Lee Hamm; Crystal Gadegbeku; Edward Horwitz; Raymond R Townsend; Cheryl A M Anderson; James P Lash; Chi-Yuan Hsu; Mary B Leonard; Myles Wolf
Journal:  Kidney Int       Date:  2011-03-09       Impact factor: 10.612

Review 7.  Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.

Authors:  Dennis Andress
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment.

Authors:  Cheryl P Sanchez
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Association between ambient carbon monoxide and secondary hyperparathyroidism in nondiabetic patients undergoing peritoneal dialysis.

Authors:  Cheng-Hao Weng; Ching-Chih Hu; Tzung-Hai Yen; Wen-Hung Huang
Journal:  Ther Clin Risk Manag       Date:  2015-09-16       Impact factor: 2.423

Review 10.  Chronic kidney disease mineral and bone disorder in children.

Authors:  Katherine Wesseling; Sevcan Bakkaloglu; Isidro Salusky
Journal:  Pediatr Nephrol       Date:  2007-11-28       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.